4.0 Article

Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment

Journal

ARTHRITIS AND RHEUMATISM
Volume 64, Issue 8, Pages 2773-2780

Publisher

WILEY-BLACKWELL
DOI: 10.1002/art.34458

Keywords

-

Categories

Funding

  1. Agency for Healthcare Research and Quality (AHRQ)
  2. FDA, US Department of Health and Human Services [1U18-HS-017919-0]
  3. NIH through the University of Alabama at Birmingham Center for Clinical and Translational Science [5KL2-RR-025776]
  4. NIH [5P60-AR-56116, AR-053351]
  5. AHRQ [R01-HS-018517]
  6. Novartis
  7. Pfizer
  8. Abbott
  9. Merck
  10. Amgen
  11. Millennium
  12. Centocor
  13. Eli Lilly
  14. Savient
  15. Ardea
  16. Regeneron
  17. URL
  18. Genentech
  19. Wyeth
  20. Bristol-Myers Squibb
  21. Crescendo
  22. Roche/Genentech
  23. UCB
  24. Consortium of Rheumatology Researchers of North America

Ask authors/readers for more resources

Objective To compare the incidence of hospitalized bacterial infections among children with and children without juvenile idiopathic arthritis (JIA) and to examine the effects of selected medications. Methods Using national Medicaid data from 2000 through 2005, we identified a cohort of children with JIA and a comparator cohort of children with attention deficit hyperactivity disorder (ADHD). Exposures to methotrexate (MTX), TNF inhibitors, and oral glucocorticoids (GCs) were determined using pharmacy claims. Patients hospitalized with bacterial infections were identified using coded discharge diagnoses. We calculated adjusted hazard ratios (HRadj) to compare infection incidence rates while adjusting for relevant covariates. Results We identified 8,479 JIA patients with 13,003 person-years of followup; 36% took MTX and 16% took TNF inhibitors. Compared with ADHD patients, JIA patients who were not currently taking MTX or TNF inhibitors had an increased rate of infection (HRadj 2.0 [95% confidence interval (95% CI) 1.5, 2.5]). Among JIA patients not receiving TNF inhibitor therapy, MTX users had a similar rate of infection as those not currently taking MTX (HRadj 1.2 [95% CI 0.9, 1.7]). TNF inhibitor use (irrespective of MTX) resulted in a similar rate of infection as use of MTX without a TNF inhibitor (HRadj 1.2 [95% CI 0.8, 1.8]). Use of high-dose GCs (=10 mg/day of prednisone or equivalent) increased the rate of infection as compared with no GC use, after adjustment for MTX and TNF inhibitor use (HRadj 3.1 [95% CI 2.0, 4.7]). Conclusion Children with JIA had an increased rate of infection compared to children with ADHD. Among children with JIA, the rate of infection was not increased with MTX or TNF inhibitor use, but was significantly increased with high-dose GC use.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.0
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available